FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2394715858> ?p ?o ?g. }

• W2394715858 endingPage "e298" @default.
• W2394715858 startingPage "e291" @default.
• W2394715858 abstract "Introduction In 2014, the NRG Oncology Group initiated the first National Cancer Institute-sponsored, phase 1 clinical trial of stereotactic body radiation therapy (SBRT) for the treatment of multiple metastases in multiple organ sites (BR001; NCT02206334). The primary endpoint is to test the safety of SBRT for the treatment of 2 to 4 multiple lesions in several anatomic sites in a multi-institutional setting. Because of the technical challenges inherent to treating multiple lesions as their spatial separation decreases, we present the technical requirements for NRG-BR001 and the rationale for their selection. Methods and materials Patients with controlled primary tumors of breast, non-small cell lung, or prostate are eligible if they have 2 to 4 metastases distributed among 7 extracranial anatomic locations throughout the body. Prescription and organ-at-risk doses were determined by expert consensus. Credentialing requirements include (1) irradiation of the Imaging and Radiation Oncology Core phantom with SBRT, (2) submitting image guided radiation therapy case studies, and (3) planning the benchmark. Guidelines for navigating challenging planning cases including assessing composite dose are discussed. Results Dosimetric planning to multiple lesions receiving differing doses (45-50 Gy) and fractionation (3-5) while irradiating the same organs at risk is discussed, particularly for metastases in close proximity (≤5 cm). The benchmark case was selected to demonstrate the planning tradeoffs required to satisfy protocol requirements for 2 nearby lesions. Examples of passing benchmark plans exhibited a large variability in plan conformity. Discussion NRG-BR001 was developed using expert consensus on multiple issues from the dose fractionation regimen to the minimum image guided radiation therapy guidelines. Credentialing was tied to the task rather than the anatomic site to reduce its burden. Every effort was made to include a variety of delivery methods to reflect current SBRT technology. Although some simplifications were adopted, the successful completion of this trial will inform future designs of both national and institutional trials and would allow immediate clinical adoption of SBRT trials for oligometastases." @default.
• W2394715858 created "2016-06-24" @default.
• W2394715858 creator A5001562050 @default.
• W2394715858 creator A5006856433 @default.
• W2394715858 creator A5019525982 @default.
• W2394715858 creator A5032086942 @default.
• W2394715858 creator A5042756485 @default.
• W2394715858 creator A5043086504 @default.
• W2394715858 creator A5044276002 @default.
• W2394715858 creator A5051336062 @default.
• W2394715858 creator A5055476105 @default.
• W2394715858 creator A5062040958 @default.
• W2394715858 creator A5066986846 @default.
• W2394715858 creator A5068359755 @default.
• W2394715858 creator A5079985074 @default.
• W2394715858 creator A5080926874 @default.
• W2394715858 creator A5083473334 @default.
• W2394715858 date "2016-11-01" @default.
• W2394715858 modified "2023-10-12" @default.
• W2394715858 title "Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases" @default.
• W2394715858 cites W1969919385 @default.
• W2394715858 cites W1969931281 @default.
• W2394715858 cites W2022980644 @default.
• W2394715858 cites W2031688279 @default.
• W2394715858 cites W2097593062 @default.
• W2394715858 cites W2100699934 @default.
• W2394715858 cites W2106598609 @default.
• W2394715858 cites W2136706275 @default.
• W2394715858 cites W2137602317 @default.
• W2394715858 cites W2138895002 @default.
• W2394715858 cites W2144253831 @default.
• W2394715858 cites W2145754044 @default.
• W2394715858 cites W2166459387 @default.
• W2394715858 cites W2167270572 @default.
• W2394715858 cites W4239112513 @default.
• W2394715858 cites W4240340450 @default.
• W2394715858 doi "https://doi.org/10.1016/j.prro.2016.05.004" @default.
• W2394715858 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5099083" @default.
• W2394715858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27345129" @default.
• W2394715858 hasPublicationYear "2016" @default.
• W2394715858 type Work @default.
• W2394715858 sameAs 2394715858 @default.
• W2394715858 citedByCount "47" @default.
• W2394715858 countsByYear W23947158582016 @default.
• W2394715858 countsByYear W23947158582017 @default.
• W2394715858 countsByYear W23947158582018 @default.
• W2394715858 countsByYear W23947158582019 @default.
• W2394715858 countsByYear W23947158582020 @default.
• W2394715858 countsByYear W23947158582021 @default.
• W2394715858 countsByYear W23947158582022 @default.
• W2394715858 countsByYear W23947158582023 @default.
• W2394715858 crossrefType "journal-article" @default.
• W2394715858 hasAuthorship W2394715858A5001562050 @default.
• W2394715858 hasAuthorship W2394715858A5006856433 @default.
• W2394715858 hasAuthorship W2394715858A5019525982 @default.
• W2394715858 hasAuthorship W2394715858A5032086942 @default.
• W2394715858 hasAuthorship W2394715858A5042756485 @default.
• W2394715858 hasAuthorship W2394715858A5043086504 @default.
• W2394715858 hasAuthorship W2394715858A5044276002 @default.
• W2394715858 hasAuthorship W2394715858A5051336062 @default.
• W2394715858 hasAuthorship W2394715858A5055476105 @default.
• W2394715858 hasAuthorship W2394715858A5062040958 @default.
• W2394715858 hasAuthorship W2394715858A5066986846 @default.
• W2394715858 hasAuthorship W2394715858A5068359755 @default.
• W2394715858 hasAuthorship W2394715858A5079985074 @default.
• W2394715858 hasAuthorship W2394715858A5080926874 @default.
• W2394715858 hasAuthorship W2394715858A5083473334 @default.
• W2394715858 hasBestOaLocation W23947158582 @default.
• W2394715858 hasConcept C126322002 @default.
• W2394715858 hasConcept C126838900 @default.
• W2394715858 hasConcept C19527891 @default.
• W2394715858 hasConcept C201645570 @default.
• W2394715858 hasConcept C203092338 @default.
• W2394715858 hasConcept C2989005 @default.
• W2394715858 hasConcept C509974204 @default.
• W2394715858 hasConcept C535046627 @default.
• W2394715858 hasConcept C71924100 @default.
• W2394715858 hasConceptScore W2394715858C126322002 @default.
• W2394715858 hasConceptScore W2394715858C126838900 @default.
• W2394715858 hasConceptScore W2394715858C19527891 @default.
• W2394715858 hasConceptScore W2394715858C201645570 @default.
• W2394715858 hasConceptScore W2394715858C203092338 @default.
• W2394715858 hasConceptScore W2394715858C2989005 @default.
• W2394715858 hasConceptScore W2394715858C509974204 @default.
• W2394715858 hasConceptScore W2394715858C535046627 @default.
• W2394715858 hasConceptScore W2394715858C71924100 @default.
• W2394715858 hasIssue "6" @default.
• W2394715858 hasLocation W23947158581 @default.
• W2394715858 hasLocation W23947158582 @default.
• W2394715858 hasLocation W23947158583 @default.
• W2394715858 hasLocation W23947158584 @default.
• W2394715858 hasOpenAccess W2394715858 @default.
• W2394715858 hasPrimaryLocation W23947158581 @default.
• W2394715858 hasRelatedWork W1562768246 @default.
• W2394715858 hasRelatedWork W1602261451 @default.
• W2394715858 hasRelatedWork W2003305474 @default.
• W2394715858 hasRelatedWork W2031643092 @default.
• W2394715858 hasRelatedWork W2041795146 @default.

• next